CAPPELLO, EMILIANO
 Distribuzione geografica
Continente #
NA - Nord America 406
EU - Europa 403
AS - Asia 173
AF - Africa 53
OC - Oceania 8
SA - Sud America 1
Totale 1.044
Nazione #
US - Stati Uniti d'America 400
SE - Svezia 149
IT - Italia 137
IN - India 58
SG - Singapore 48
GB - Regno Unito 46
CI - Costa d'Avorio 31
BG - Bulgaria 28
JP - Giappone 16
SN - Senegal 13
DE - Germania 11
HK - Hong Kong 11
FR - Francia 9
IR - Iran 9
KR - Corea 9
AU - Australia 8
FI - Finlandia 8
NG - Nigeria 8
CA - Canada 6
CN - Cina 4
ID - Indonesia 4
VN - Vietnam 4
TR - Turchia 3
CH - Svizzera 2
CZ - Repubblica Ceca 2
ES - Italia 2
IL - Israele 2
PK - Pakistan 2
PL - Polonia 2
PT - Portogallo 2
CL - Cile 1
ET - Etiopia 1
GR - Grecia 1
IE - Irlanda 1
KZ - Kazakistan 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
SI - Slovenia 1
TH - Thailandia 1
Totale 1.044
Città #
Ashburn 61
Chandler 44
Boardman 36
Florence 35
Abidjan 31
Sofia 28
Serra 27
London 26
Singapore 21
Kent 20
New York 20
Princeton 17
Fairfield 15
Hyderabad 15
Pisa 14
Dakar 13
Lawrence 13
Mumbai 13
Hong Kong 10
Medford 9
Ogden 9
Wilmington 9
Lagos 8
Jeju City 6
Los Angeles 6
Washington 6
Cambridge 5
Lappeenranta 5
Marseille 5
New Malden 5
Birmingham 4
Jakarta 4
Pomona 4
Redwood City 4
Scarlino 4
Chicago 3
Denver 3
Esslingen am Neckar 3
Houston 3
Jamshedpur 3
Kariya 3
Melbourne 3
Porto Azzurro 3
Rome 3
Turin 3
Woodbridge 3
Ōmura 3
Ann Arbor 2
Bengaluru 2
Bremen 2
Charlotte 2
Dallas 2
Dongjak-gu 2
Edgware 2
Fiesole 2
Füllinsdorf 2
Helsinki 2
Istanbul 2
Kolkata 2
Lisbon 2
Mardi 2
Miami 2
Naples 2
New Delhi 2
Oklahoma City 2
Pensacola 2
Peshawar 2
Prato 2
Raleigh 2
San Francisco 2
Sheridan 2
Stillwater 2
Tokyo 2
Toronto 2
Vancouver 2
Warsaw 2
West Hempstead 2
Westhill 2
Alba Adriatica 1
Almaty 1
Bacoli 1
Baltimore 1
Beijing 1
Brno 1
Chennai 1
City of Westminster 1
Cogorno 1
Delhi 1
Dong Ket 1
Dublin 1
Duncan 1
Encino 1
Fort Wayne 1
Fremont 1
Gaeta 1
Gurugram 1
Harlingen 1
Jerusalem 1
Ljubljana 1
Llanelli 1
Totale 672
Nome #
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 90
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 85
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 80
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 70
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 66
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 65
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 63
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 61
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 55
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study 54
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 53
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase 52
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance 51
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 48
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. 34
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. 20
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis 14
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World 13
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 11
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option 11
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project 10
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO 9
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 8
Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data 8
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients 8
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study 8
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence 7
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study 7
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring 7
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) 6
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database 5
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 5
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall 4
Totale 1.088
Categoria #
all - tutte 5.580
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.580


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202128 0 0 0 0 0 0 0 0 0 0 6 22
2021/2022279 4 2 39 51 48 22 13 10 13 8 20 49
2022/2023318 50 71 26 12 16 22 17 4 66 0 34 0
2023/2024379 2 9 19 3 28 41 51 36 32 25 66 67
2024/202584 26 58 0 0 0 0 0 0 0 0 0 0
Totale 1.088